Literature DB >> 29753099

Validation of the Dyspnea Exertion Scale of Breathlessness in People With Life-Limiting Illness.

Jacob Sandberg1, Miriam J Johnson2, David C Currow3, Magnus Ekström4.   

Abstract

BACKGROUND: Although chronic breathlessness is common in life-limiting illnesses, validated feasible instruments to measure functional impact of the symptom in this population are scarce. We aimed to validate the Dyspnea Exertion Scale (DES) compared with the modified Medical Research Council (mMRC) breathlessness scale for test-retest reliability, concurrent validity, and responsiveness in people with life-limiting illness.
METHODS: A total of 188 participants, 66% males, with chronic breathlessness, mostly (70%) because of chronic pulmonary disease (chronic obstructive pulmonary disease) self-reported evening scores of mMRC, DES, Numerical Rating Scale (NRS), and Eastern Cooperative Oncology Group during nine days.
RESULTS: About 44% (n = 81) scored the highest score on mMRC indicating a ceiling effect not seen with DES. Both scales had moderate-to-good test-retest agreement (89% DES; 84% mMRC; P < 0.001 for both). Analyses for concurrent validity showed that higher DES and mMRC scores were correlated with higher NRS breathlessness intensity scores and Eastern Cooperative Oncology Group scores throughout the nine days. In longitudinal analyses, DES (r = 0.30; P < 0.001) was more responsive to change in NRS score during nine days than the mMRC (r = 0.16; P = 0.03).
CONCLUSION: Compared with mMRC, DES had comparable or better measurement properties in terms of test-retest reliability and concurrent validity and could be used as a discriminative tool in this population, but both scales are too insensitive to change to be used as an outcome in clinical trials.
Copyright © 2018 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breathlessness; DES; Dyspnea Exertion Scale (DES); Medical Research Council breathlessness scale; mMRC; measurement; validation

Mesh:

Year:  2018        PMID: 29753099     DOI: 10.1016/j.jpainsymman.2018.05.002

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  2 in total

1.  Impact of covid-19 on long-term oxygen therapy 2020: A nationwide study in Sweden.

Authors:  Josefin Sundh; Andreas Palm; Josefin Wahlberg; Michael Runold; Magnus Ekström
Journal:  PLoS One       Date:  2022-04-08       Impact factor: 3.240

2.  Clinimetrics: Core Outcome Set for trials with Coronavirus disease 2019 (COVID-19-COS).

Authors:  Mariana Hoffman; Anne E Holland
Journal:  J Physiother       Date:  2021-07-14       Impact factor: 7.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.